Læknablaðið - 15.02.1996, Page 41

LÆKNABLAÐIÐ 1996; 82
147
Þakkir
Verkefnið naut styrkja úr Vísindasjóði Is-
lands, rannsóknasjóði Krabbameinsfélags ís-
lands og starfslaunasjóði sjúkrahúslækna.
Starfsfólki eftirfarandi deilda er þakkað
samstarf og velvilji við gagnasöfnun: Krabba-
meinslækningadeildar Landspítalans, Rann-
sóknastofu Háskólans í meinafræði, Krabba-
meinsskrár Krabbameinsfélags íslands, Tölvu-
vers Landspítalans og skurðdeilda
Landspítala, Borgarspítala, Landakotsspítala,
Fjórðungssjúkrahússins á Akureyri og Sjúkra-
húss Akraness.
HEIMILDIR
1. Tulinius H, Bjarnason O, Sigvaldason H, Bjamadóttir
G, Olafsdottir G. Tumors in Iceland. 10. Malignant tu-
mors of the female breast. A histological classification,
laterality, survival and epidemiological consideration.
APMIS 1988; 96: 229-38.
2. Glass AG, Hoover RN. Rising incidence of breast can-
cer: relationship to stage and receptor status. J Natl
Cancer Inst 1990; 82: 693-6.
3. Skýrsla 1993, Krabbameinsfélagið. Lögð fram á aðal-
fundi Krabbameinsfélags íslands 28. maí 1992. Reykja-
vík: Krabbameinsfélagið, 1993: 24-36.
4. Ragnarsson J. Priðji til fjórði hver íslendingur fær
krabbamein fyrir áttrætt. Heilbrigðismál 1992; 40: 5.
5. Blamey R. Does biological understanding influence sur-
gical practice? Br J Cancer 1989; 60: 271—4.
6. McGuire WL, Tandon AK, Allred DC, Chamness GC,
Clark GM. How to use prognostic factors in axillary
node-negative breast cancer patients. J Natl Cancer Inst
1990; 82: 1006-14.
7. Early Breast Cancer, Trialists Collaborative Group.
Systemic treatment of early breast cancer by hormonal,
cytotoxic, or immune therapy. 133 randomised trials
involving 31000 recurrences and 24000 deaths among
75000 women. Lancet 1992; 339: 1-15, 71-85.
8. Clinical alert from the National Cancer Institute. Breast
Cancer Res Treat 1988; 12: 3-5.
9. McGuire WL. Adjuvant therapy of node-negative
breast cancer: another point of view. J Natl Cancer Inst
1988; 80: 1075-6.
10. Sigurdsson H, Baldetorp B, Borg A, Fernö M, Kellan-
der D, Olsson H. Indicators of prognosis in node-nega-
tive breast cancer. N Engl J Med 1990; 322: 1045-53.
11. Barr L, Baum M. Time to abandon TNM staging of
breast cancer. Lancet 1992; 339: 915-7.
12. Fisher B, Redmond C, Fisher E, Caplan R. Relative
worth of estrogen or progesterone receptor and path-
ologic characteristics of differentiation as indicators of
prognosis in node negative breast cancer: Findings from
National Surgical Adjuvant Breast and Bowe! Project
Protocol B-06. J Clin Onc 1988; 6: 1076-87.
13. Silvestrini R, Daidone MG, Valagussa P, Di Fronzo G,
Mezzanotte G, Mariani L, et al. 3H-thymidine-labeling
index as a prognostic indicator in node-positive breast
cancer. J Clin Oncol 1990; 8: 1321-6.
14. Fallenius AG, Auer GU, Carstensen JM. Prognostic
significance of DNA measurements in 409 consecutive
breast cancer patients. Cancer 1988; 62: 331—41.
15. Clark GM, Dressler LG, Owens MA, Pounds G, Oldak-
er T, Mc Guire WL. Prediction of relapse or survival in
patients with node-negative breast cancer by DNA flow
cytometry. N Engl J Med 1989; 320: 627-33.
16. Hedley DW, Rugg CA, Gelber RD. Association of
DNA index and S-phase fraction with prognosis of
nodes positive early breast cancer. Cancer Res 1987; 47:
4729-35.
17. Kallioniemi OP, Blanco G, Alavaikko M, Hietanen T,
Mattila J, Lanslahti K, et al. Improving the prognostic
value of DNA flow cytometry in breast cancer by com-
bining DNA index and S-phase fraction. A proposed
classification of DNA histograms in breast cancer. Can-
cer 1988; 62: 2183-90.
18. O’Reilly SM, Camplejohn RS, Barnes DM, Millis RR,
Allen D, Rubens RD, et al. DNA index, S-phase frac-
tion, histological grade and prognosis in breast cancer.
Br J Cancer 1990; 61: 671-4.
19. Toikkanen S, Joensuu H, Klemi P. The prognostic sig-
nificance of nuclear DNA content in invasive breast
cancer-a study with long-term follow-up. Br J Cancer
1989; 60: 693-700.
20. Kute TE, Muss HB, Cooper MR, Case LD, Buss P,
Stanley V, et al. The use of flow cytometry for prognosis
of stage II adjuvant breast cancer patients. Cancer 1990;
66: 1810-6.
21. UICC: International Union Against Cancer. TNM clas-
sification of malignant tumors. Geneva: UICC, 1982.
22. Thorpe S, Poulsen HS, Pedersen KO, Rose C. Quality
control of receptor analysis of breast cancer tissue in
Denmark. Acta Oncol 1988; 27/Suppl.: 621-5.
23. Thornthwaite JT, Sugerbaker EV, Temple WJ. Prep-
aration of tissues for DNA flow cytometric analysis.
Cytometry 1980; 1: 229-37.
24. Hedley DW, Friedlander ML, Taylor IW. Application
of DNA flow cytometry to paraffin-embedded archival
material for the study of aneuploidy and its clinical sig-
nificance. Cytometry 1985; 6: 327-33.
25. Hiddeman W, Schumann J, Andreeff M, Barlogie B,
Herman CJ, Leif RC, et al. Convention of nomenclature
for DNA cytometry. Cytometry 1984; 5: 445-6.
26. Baisch H, Gohde W, Linden WA. Analysis of PCP-data
to determine the fraction of cells in various phases of cell
cycle. Rad Environm Biophys 1975; 12: 31-9.
27. Kaplan EL, Meier P. Nonparametric estimation from
incomplete observations. J Amer Statist Assoc 1958; 53:
457-81.
28. Mantel N. Evaluation of survival data and two new rank
order statistics arising in its consideration. Cancer Che-
mother Rep 1966; 50: 163-70.
29. Cox DR. Regression models and life tables (with dis-
cussion). J Roy Stat Soc B 1972; 34: 187-220.
30. Sigurdsson H. Indicators of prognosis in breast cancer
with emphasis on flow cytometric DNA analysis of ploi-
dy and S-phase fraction. Lund: G. Ben. prentstofa hf.,
1992.
31. McGuire WL. Breast cancer prognostic factors: eval-
uation guidelines. J Natl Cancer Inst 1990; 83: 154-5.
32. Höst H, Lund E. Age as a prognostic factor in breast
cancer. Cancer 1986; 57: 2217-21.
33. Sigurdsson H, Baldetorp B, Borg Á, Dalberg M, Fernö
M, Kellander D, et al. Flow cytometry in primary breast
cancer: improving the prognostic value of the fraction of
cells in the S-phase by optimal categorization of cut-off
levels. Br J Cancer 1990; 62: 786-90.
34. Kallioniemi O-P, Karkkainen A, Auvinen O, Mattila J,
Koivula T, Hakama M. DNA flow cytometry analysis
indicates that many breast cancers detected in the first
round of mammography screening have a low malignant
potential. Int J Cancer 1988; 42: 697-702.